Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 9, 2024, to review the company's first quarter 2024 financial results and provide business updates.
馬薩諸塞州劍橋，2024年5月2日（GLOBE NEWSWIRE）——專注於釋放RNA藥物改變人類健康的廣泛潛力的臨床階段生物技術公司Wave Life Sciences Ltd.（納斯達克股票代碼：WVE）將於美國東部時間2024年5月9日星期四上午8點30分舉辦網絡直播和電話會議，審查該公司2024年第一季度的財務業績並提供業務最新情況。
The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: ir.wavelifesciences.com/events-publications/events.
網絡直播和電話會議可訪問Wave Life Sciences網站投資者專區的 “投資者活動”：ir.wavelifesciences.com/events-publications/events-publications/events-publications/events。
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. Once registered, participants will receive the dial-in information.
計劃參與實時電話問答部分的分析師可以通過以下音頻會議鏈接加入電話會議：可在此處獲得。註冊後，參與者將收到撥入信息。
Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
直播結束後，網絡直播的存檔版本將在Wave Life Sciences網站上公佈。
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington's disease, as well as a preclinical program in obesity. Driven by the calling to "Reimagine Possible", Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit and follow Wave on X (formerly Twitter) and LinkedIn.
關於 Wave 生命科學
Wave Life Sciences（納斯達克股票代碼：WVE）是一家生物技術公司，致力於釋放RNA藥物改變人類健康的廣泛潛力。Wave 的 RNA 藥物平台 PRISMTM，結合了多種模式、化學創新和對人類遺傳學的深刻見解，實現了治療罕見和流行疾病的科學突破。其RNA靶向模式工具包包括編輯、剪接、RNA干擾和反義沉默，爲Wave設計和可持續交付最適合疾病生物學的候選藥物提供了無與倫比的能力。Wave的多元化項目包括杜興氏肌肉萎縮症、Alpha-1抗胰蛋白酶缺乏症和亨廷頓氏病的臨床項目，以及肥胖症的臨床前項目。在 “重新構想可能” 的號召下，Wave正在引領人們走向一個人類潛能不再受到疾病負擔阻礙的世界。Wave 總部位於馬薩諸塞州劍橋。有關Wave的科學、管道和人員的更多信息，請在X（前身爲推特）和領英上訪問並關注Wave。
Investor Contact:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com
投資者聯繫人：
凱特·勞什
+1 617-949-4827
krausch@wavelifesci.com
Media Contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com
媒體聯繫人：
艾麗西亞·蘇特
+1 617-949-4817
asuter@wavelifesci.com
譯文內容由第三人軟體翻譯。